What happened with ATR today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
AptarGroup supplies pharmaceutical and consumer-product companies with the parts that let people use their products, such as nasal spray pumps, inhaler valves and lotion pumps. Customers generally order components at agreed prices for use in their own products. Pharma is its largest revenue source: it supplies drug-delivery devices, seals and protective packaging, including stoppers for medicine vials and components for prefilled syringes. It also sells services that help pharmaceutical customers develop drugs and navigate regulatory approvals.
Beauty is the next-largest business, supplying dispensing systems for fragrance, skincare and personal-care products. The smaller Closures business makes caps that let users dispense a product without removing the cap, serving food, beverage and other consumer-product companies.
AptarGroup has a broad customer base, with no single customer accounting for a large share of sales. Its pharmaceutical business depends partly on customers securing regulatory approval and commercial success for drugs paired with its devices. FDA and comparable overseas regulation can delay sales or limit permitted uses. Production also relies on specialized suppliers, with some pharmaceutical materials sourced from only one supplier.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
AptarGroup’s earnings depend chiefly on demand for pharmaceutical dispensing and protection, including nasal medicines and GLP-1 injectable components, rather than the broader packaging cycle.
Silgan competes directly with AptarGroup to sell dispensing systems and specialty closures to packaging customers. Watch this business’s sales and profit: in 2025 it generated roughly half of Silgan’s EBIT before corporate expense, making it a substantial rival to Aptar’s pumps and closures.
Amcor competes with AptarGroup for health, beauty and food brands buying dispensing and closure solutions. Its work on packaging tailored to those customers is the relevant overlap for Aptar holders, rather than Amcor’s entire flexible and rigid packaging business.
ARS Pharmaceuticals buys parts from AptarGroup for neffy, its nasal epinephrine product, tying Aptar to this customer’s drug business while the supply relationship faces antitrust and trade-secret litigation. Watch neffy sales to U.S. pharmaceutical wholesalers and developments in those lawsuits for signals about Aptar’s nasal-drug component business.
EIA Crude Oil Stocks Change (Oct/16)
For Aptar, weekly US reports on crude oil and gasoline stocks indicate whether oil and fuel supply is tightening or loosening, which can shift the energy and transportation costs it pays to make and ship dispensing and packaging products.
Read larger crude and gasoline stocks as a sign of looser supply that tends to ease oil and fuel prices, potentially reducing Aptar’s energy and transportation costs; smaller stocks point to tighter supply and potential cost pressure.
AptarGroup, Inc. earningsThis company
AptarGroup’s report will show whether sales of its drug-delivery, dispensing and closure products can grow without input and production costs squeezing segment margins.
Read core sales growth alongside each segment’s adjusted EBITDA margin, which measures segment earnings before interest, taxes, depreciation and amortization. Growing core sales with steady or rising margins would show that demand and pricing are covering material and production costs; slowing sales or falling margins would point to weaker demand, rising costs or limited ability to pass them on, weakening AptarGroup’s growth quality.
Silgan Holdings Inc earningsSLGN
Silgan’s report will show how sales and profit are holding up in dispensing systems and specialty closures, product lines that compete with AptarGroup’s pumps and closures.
Look at sales and profit in Silgan’s dispensing-systems and specialty-closures business together. Growth in both would indicate that packaging customers still want these overlapping products; weaker sales or profit would signal pressure in the shared market and a tougher demand or competitive environment for AptarGroup’s pumps and closures.
ARS Pharmaceuticals, Inc. earningsSPRY
ARS Pharmaceuticals, Inc.’s report will show how neffy sales to U.S. pharmaceutical wholesalers are doing, offering a signal about demand from a customer for AptarGroup’s nasal-drug components.
Watch neffy sales to U.S. pharmaceutical wholesalers. Stronger sales would show growing demand for this customer’s nasal epinephrine drug and could support demand for AptarGroup’s related nasal-drug components; weaker sales would mean less support from this customer. Litigation may affect the supply relationship, but this report alone cannot settle the lawsuits or establish AptarGroup’s actual sales.
